Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. reduced its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 27.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,711 shares of the company's stock after selling 8,737 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in Guardant Health were worth $694,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Arizona State Retirement System increased its stake in shares of Guardant Health by 1.1% during the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock worth $1,089,000 after purchasing an additional 403 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock worth $82,000 after buying an additional 817 shares during the last quarter. Fiduciary Alliance LLC increased its stake in shares of Guardant Health by 7.6% in the 4th quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock worth $363,000 after acquiring an additional 836 shares during the last quarter. R Squared Ltd purchased a new position in shares of Guardant Health during the 4th quarter worth $26,000. Finally, Van ECK Associates Corp boosted its holdings in Guardant Health by 47.4% in the 4th quarter. Van ECK Associates Corp now owns 2,887 shares of the company's stock valued at $88,000 after purchasing an additional 929 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Raymond James reiterated an "outperform" rating and issued a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research report on Friday, February 21st. Stephens restated an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a research report on Wednesday, March 26th. JPMorgan Chase & Co. lifted their target price on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. Guggenheim restated a "buy" rating and issued a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Finally, Scotiabank upped their price target on Guardant Health from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Twenty equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Guardant Health presently has a consensus rating of "Buy" and an average target price of $49.00.

Guardant Health Stock Performance

Shares of GH stock traded up $2.57 during mid-day trading on Friday, hitting $43.71. 2,167,377 shares of the stock were exchanged, compared to its average volume of 2,139,587. The stock's fifty day simple moving average is $43.57 and its two-hundred day simple moving average is $35.69. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $50.89. The stock has a market capitalization of $5.39 billion, a price-to-earnings ratio of -12.28 and a beta of 1.45.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.